Albireo Pharma, Inc. (ALBO) News

Albireo Pharma, Inc. (ALBO): $20.70

0.65 (+3.24%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter ALBO News Items

ALBO News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

ALBO News Highlights

  • ALBO's 30 day story count now stands at 7.
  • Over the past 21 days, the trend for ALBO's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
  • RARE, NICE and BEAT are the most mentioned tickers in articles about ALBO.

Latest ALBO News From Around the Web

Below are the latest news stories about Albireo Pharma Inc that investors may wish to consider to help them evaluate ALBO as an investment opportunity.

Intellia Therapeutics, Inc. (NTLA) Reports Q4 Loss, Tops Revenue Estimates

Intellia Therapeutics, Inc. (NTLA) delivered earnings and revenue surprises of -19.78% and 33.35%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | February 24, 2022

The Zacks Analyst Blog Highlights Teladoc Health, Albireo Pharma and The Joint Corp

Teladoc Health, Albireo Pharma and The Joint Corp are included in this blog.

Yahoo | February 22, 2022

Albireo to Report Q4 and Year-End 2021 Financial Results on March 1

— Conference call and webcast to be held at 10:00 a.m. ET —BOSTON, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced that management will host a conference call and live audio webcast at 10:00 a.m. ET on March 1, 2022, to provide a business update and review the company’s financial results for the fourth quarter and year ended December 31, 2021. To access the live conference call by phone, di

Yahoo | February 22, 2022

NICE Recommends Albireo’s Bylvay® (odevixibat) for All PFIC Types

– Decision provides access to the first drug treatment approved in PFIC for patients in England, Wales and Northern Ireland – Positive NICE review completed in less than six months post MHRA approval – NICE review is first successful clinical & economic benefit assessment of Bylvay completed in Europe – Bylvay already submitted for reimbursement in multiple European countries BOSTON, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing no

Yahoo | February 22, 2022

Albireo Pharma (ALBO) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

Albireo Pharma (ALBO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | February 17, 2022

Albireo Announces Publication of the PICTURE Study Highlighting the Caregiver Impact of PFIC, a Rare and Devastating Children’s Liver Disease

PFIC caregivers reported high impact on mental and physical health, productivity, career prospects, sleep, relationships and financesStudy suggests PFIC caregivers’ quality of life may be comparable to that of cystic fibrosis caregivers BOSTON, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced the publication of the PICTURE study in Orphanet Journal of Rare Disease. A multinational, retrospec

Yahoo | February 14, 2022

10 Biotech Stocks to Buy According to Matthew Strobeck’s Birchview Capital

In this article, we discuss 10 biotech stocks to buy according to Matthew Strobeck’s Birchview Capital. If you want to skip our detailed analysis of Strobeck’s history, investment philosophy, and hedge fund performance, go directly to 5 Biotech Stocks to Buy According to Matthew Strobeck’s Birchview Capital. Matthew Strobeck earned his Ph.D. from the University […]

Yahoo | February 3, 2022

When Can We Expect A Profit From Albireo Pharma, Inc. (NASDAQ:ALBO)?

We feel now is a pretty good time to analyse Albireo Pharma, Inc.'s ( NASDAQ:ALBO ) business as it appears the company...

Yahoo | January 19, 2022

Wall Street Analysts Predict an 184% Upside in Albireo Pharma (ALBO): Here's What You Should Know

The average of price targets set by Wall Street analysts indicates a potential upside of 183.9% in Albireo Pharma (ALBO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Yahoo | January 12, 2022

Is Adial Pharmaceuticals, Inc. (ADIL) Outperforming Other Medical Stocks This Year?

Here is how Adial Pharmaceuticals, Inc. (ADIL) and Albireo Pharma (ALBO) have performed compared to their sector so far this year.

Yahoo | January 12, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.4374 seconds.